ESMO-BC 2026

May 06-08, 2026
Berlin, Germany

The ESMO Breast Cancer Congress 2026

Explore more Oncology congress materials

Results(1)

Oncology

Exploratory biomarker analysis from a phase 1b/2 trial of zanidatamab + evorpacept in patients with HER2-positive metastatic breast cancer

Author(s): Funda Meric-Bernstam, Kari B Wisinski, Bruno Fang et al.

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.